Go Pro
NASDAQ:FENC

Adherex Technologies (FENC) Stock Price, News & Analysis

Adherex Technologies logo
$10.55 -0.09 (-0.85%)
Closing price 09/16/2026 04:00 PM Eastern
Extended Trading
$10.56 +0.01 (+0.09%)
As of 09/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Adherex Technologies Stock (NASDAQ:FENC)

Advanced

Key Stats

Today's Range
$10.52
$10.96
50-Day Range
$9.57
$12.78
52-Week Range
$5.65
$13.25
Volume
170,327 shs
Average Volume
256,639 shs
Market Capitalization
$369.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00
Consensus Rating
Moderate Buy

Company Overview

Adherex Technologies Inc. was a biotechnology company that focused on developing therapies for cancer treatment and treatment-related complications. The company is now known as Fennec Pharmaceuticals Inc. and trades on the Nasdaq under the symbol FENC.

Fennec’s principal product is PEDMARK (sodium thiosulfate), a formulation designed to reduce the risk of cisplatin-induced ototoxicity, or hearing loss, in children receiving cisplatin chemotherapy for localized, non-metastatic solid tumors. Cisplatin is widely used in cancer treatment but can cause permanent damage to hearing, particularly in pediatric patients.

The company’s activities are centered on the development and commercialization of PEDMARK for pediatric oncology. Fennec serves the U.S. market and has pursued regulatory and commercial opportunities in other regions. The company’s current business represents the continuation of Adherex’s oncology-focused development efforts under the Fennec Pharmaceuticals name.

AI Generated. May Contain Errors.

Adherex Technologies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
78th Percentile Overall Score

FENC MarketRank™: 

Adherex Technologies scored higher than 78% of companies evaluated by MarketBeat, and ranked 116th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adherex Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Adherex Technologies has a consensus price target of $17.00, representing about 61.1% upside from its current price of $10.55.

  • Amount of Analyst Coverage

    Adherex Technologies has only been the subject of 4 research reports in the past 90 days.

  • Read more about Adherex Technologies' stock forecast and price target.
  • Earnings Growth

    Earnings for Adherex Technologies are expected to grow by 246.43% in the coming year, from $0.28 to $0.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adherex Technologies is -81.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adherex Technologies is -81.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adherex Technologies has a P/B Ratio of 10.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Adherex Technologies' valuation and earnings.
  • Percentage of Shares Shorted

    1.66% of the float of Adherex Technologies has been sold short.
  • Short Interest Ratio / Days to Cover

    Adherex Technologies has a short interest ratio ("days to cover") of 2.03, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adherex Technologies has recently decreased by 2.15%, indicating that investor sentiment is improving.
  • Dividend Yield

    Adherex Technologies does not currently pay a dividend.

  • Dividend Growth

    Adherex Technologies does not have a long track record of dividend growth.

  • News Sentiment

    Adherex Technologies has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Adherex Technologies this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Adherex Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,029,660.00 in company stock.

  • Percentage Held by Insiders

    10.73% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Adherex Technologies' insider trading history.
Receive FENC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adherex Technologies and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FENC Stock News Headlines

What is HC Wainwright's Estimate for FENC Q3 Earnings?
Adherex Technologies (NASDAQ:FENC) Earns Buy Rating from HC Wainwright
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Adherex Technologies (NASDAQ:FENC) CFO Sells 75,000 Shares
Fennec Announces Results of Annual Meeting
See More Headlines

FENC Stock Analysis - Frequently Asked Questions

Adherex Technologies' stock was trading at $7.70 at the start of the year. Since then, FENC shares have increased by 37.0% and is now trading at $10.55.

Adherex Technologies Inc. (NASDAQ:FENC) released its earnings results on Thursday, August, 13th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The firm earned $17.87 million during the quarter, compared to analyst estimates of $16.21 million. Adherex Technologies had a negative net margin of 6.09% and a negative trailing twelve-month return on equity of 5.71%.
Read the conference call transcript
.

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adherex Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
8/13/2026
Today
9/17/2026
Next Earnings (Estimated)
11/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:FENC
CIK
1211583
Employees
35
Year Founded
1996

Price Target and Rating

High Price Target
$18.00
Low Price Target
$16.00
Potential Upside/Downside
+61.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.13)
Trailing P/E Ratio
N/A
Forward P/E Ratio
37.68
P/E Growth
N/A
Net Income
-$9.74 million
Net Margins
-6.09%
Pretax Margin
-5.24%
Return on Equity
-5.71%
Return on Assets
-2.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.85
Quick Ratio
5.66

Sales & Book Value

Annual Sales
$44.64 million
Price / Sales
8.29
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.04 per share
Price / Book
10.14

Miscellaneous

Outstanding Shares
35,060,000
Free Float
31,296,000
Market Cap
$369.88 million
Optionable
Optionable
Beta
1.10
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:FENC) was last updated on 9/17/2026 by MarketBeat.com Staff.
From Our Partners